• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, October 6, 2017

Article

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The National Pharmaceutical Council’s Daily Newsfeed e-mail on Monday highlighted a product theater published by The American Journal of Managed Care® (AJMC®). The article, “Experts Present Evidence and Advice on Canagliflozin,” discussed the presentation of the CANVAS and CANVAS-R trials at the 77th Scientific Sessions of the American Diabetes Association in San Diego, California, on June 12, 2017. The trials found that canagliflozin, a type 2 diabetes therapy, was linked to a 14% reduction in the combined endpoint of nonfatal heart attacks, nonfatal strokes, and cardiovascular death.

Related Videos
Joshua K. Sabari, MD< NYU Langone Perlmutter Cancer Center
Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"
Imran Khan, MD, PhD, Johnson & Johnson
ateyeh soroush
dr kathy zackowski
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.